ESKATA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Eskata, and what generic alternatives are available?
Eskata is a drug marketed by Aclaris and is included in one NDA. There are five patents protecting this drug.
This drug has eighteen patent family members in sixteen countries.
The generic ingredient in ESKATA is hydrogen peroxide. There are fifty-three drug master file entries for this compound. Additional details are available on the hydrogen peroxide profile page.
DrugPatentWatch® Generic Entry Outlook for Eskata
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be April 21, 2035. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for ESKATA
International Patents: | 18 |
US Patents: | 5 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 152 |
Patent Applications: | 4,290 |
Formulation / Manufacturing: | see details |
What excipients (inactive ingredients) are in ESKATA? | ESKATA excipients list |
DailyMed Link: | ESKATA at DailyMed |

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for ESKATA
Generic Entry Date for ESKATA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;TOPICAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Anatomical Therapeutic Chemical (ATC) Classes for ESKATA
US Patents and Regulatory Information for ESKATA
ESKATA is protected by five US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of ESKATA is ⤷ Try a Trial.
This potential generic entry date is based on patent ⤷ Try a Trial.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting ESKATA
Peroxide formulations and methods and applicators for using the same
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF SEBORRHEIC KERATOSES THAT ARE RAISED
Peroxide formulations and methods and applicators for using the same
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Peroxide formulations and methods and applicators for using the same
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Peroxide formulations and methods and applicators for using the same
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF SEBORRHEIC KERATOSES THAT ARE RAISED
Peroxide formulations and methods and applicators for using the same
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF SEBORRHEIC KERATOSES THAT ARE RAISED
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aclaris | ESKATA | hydrogen peroxide | SOLUTION;TOPICAL | 209305-001 | Dec 14, 2017 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Aclaris | ESKATA | hydrogen peroxide | SOLUTION;TOPICAL | 209305-001 | Dec 14, 2017 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Aclaris | ESKATA | hydrogen peroxide | SOLUTION;TOPICAL | 209305-001 | Dec 14, 2017 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Aclaris | ESKATA | hydrogen peroxide | SOLUTION;TOPICAL | 209305-001 | Dec 14, 2017 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Aclaris | ESKATA | hydrogen peroxide | SOLUTION;TOPICAL | 209305-001 | Dec 14, 2017 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ESKATA
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Aclaris | ESKATA | hydrogen peroxide | SOLUTION;TOPICAL | 209305-001 | Dec 14, 2017 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ESKATA
When does loss-of-exclusivity occur for ESKATA?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 15249841
Estimated Expiration: ⤷ Try a Trial
Brazil
Patent: 2016024630
Estimated Expiration: ⤷ Try a Trial
Canada
Patent: 46568
Estimated Expiration: ⤷ Try a Trial
China
Patent: 6659643
Estimated Expiration: ⤷ Try a Trial
Denmark
Patent: 34061
Estimated Expiration: ⤷ Try a Trial
European Patent Office
Patent: 34061
Estimated Expiration: ⤷ Try a Trial
Israel
Patent: 8462
Estimated Expiration: ⤷ Try a Trial
Japan
Patent: 22217
Estimated Expiration: ⤷ Try a Trial
Patent: 17513907
Estimated Expiration: ⤷ Try a Trial
Mexico
Patent: 16013826
Estimated Expiration: ⤷ Try a Trial
Poland
Patent: 34061
Estimated Expiration: ⤷ Try a Trial
Portugal
Patent: 34061
Estimated Expiration: ⤷ Try a Trial
Russian Federation
Patent: 11662
Estimated Expiration: ⤷ Try a Trial
Patent: 16145236
Estimated Expiration: ⤷ Try a Trial
Singapore
Patent: 201608775X
Estimated Expiration: ⤷ Try a Trial
South Korea
Patent: 170029413
Estimated Expiration: ⤷ Try a Trial
Spain
Patent: 28711
Estimated Expiration: ⤷ Try a Trial
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering ESKATA around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
European Patent Office | 1365781 | TRAITEMENT DES ACROCHORDONS (ACROCHORDON ALLEVIATION) | ⤷ Try a Trial |
World Intellectual Property Organization (WIPO) | 02064151 | ⤷ Try a Trial | |
European Patent Office | 3134061 | FORMULES DE PEROXYDE ET PROCÉDÉS ET APPLICATEURS POUR LEUR UTILISATION (PEROXIDE FORMULATIONS AND METHODS AND APPLICATORS FOR USING THE SAME) | ⤷ Try a Trial |
Russian Federation | 2711662 | ПЕРОКСИДНЫЕ КОМПОЗИЦИИ И СПОСОБЫ И АППЛИКАТОРЫ ДЛЯ ИХ ПРИМЕНЕНИЯ (PEROXIDE COMPOSITIONS AND METHODS AND APPLICATORS FOR USE THEREOF) | ⤷ Try a Trial |
Canada | 2437823 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ESKATA
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1968948 | 21C1051 | France | ⤷ Try a Trial | PRODUCT NAME: SEL DE SULFATE D'HYDROGENE DU SELUMETINIB, Y COMPRIS LES FORMES SOLVATES OU ANHYDRES DE CELUI-CI; REGISTRATION NO/DATE: EU/1/21/1552 20210619 |
3106463 | 122020000012 | Germany | ⤷ Try a Trial | PRODUCT NAME: LAROTRECTINIB ODER ANDERE PHARMAZEUTISCH ANNEHMBARE SALZE DAVON, EINSCHLIESSLICH LAROTRECTINIBSULFATE UMFASSEND LAROTRECTINIBHYDROGENSULFAT; REGISTRATION NO/DATE: EU/1/19/1385 20190919 |
3106463 | 20C1012 | France | ⤷ Try a Trial | PRODUCT NAME: LAROTRECTINIB ET/OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, EN PARTICULIER UN SULFATE DE LAROTRECTINIB TEL QUE L'HYDROGENOSULFATE DE LAROTRECTINIB; NAT. REGISTRATION NO/DATE: EU/1/19/1385 20190923; FIRST REGISTRATION: DE - EU/1/19/1385 20190923 |
3106463 | LUC00150 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: LAROTRECTINIB ET/OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, EN PARTICULIER LE SULFATE DE LAROTRECTINIB, Y COMPRIS L'HYDROGENOSULFATE DE LAROTRECTINIB; AUTHORISATION NUMBER AND DATE: EU/1/19/1385 20190923 |
1968948 | CR 2021 00044 | Denmark | ⤷ Try a Trial | PRODUCT NAME: SELUMETINIB HYDROGENSULFAT OG SOLVATER OG ANHYDRID FORMER DERAF; REG. NO/DATE: EU/1/21/1552 20210619 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |